Spider venom to treat paralysis

A team of Russian scientists together with foreign colleagues found out that the venom of crab spider Heriaeus melloteei may be used as a basis for developing treatment against hypokalemic periodic paralysis. This disease is caused by genetic mutation that leads to the occurrence of the so-called ω-currents or leakage currents via voltage-gated ion channels Nav1.4 in skeletal muscles. As a result of such "leakages" the muscles become unable to respond to the signals sent by the nervous system and a patient suffers muscle weakness up to total paralysis. There is still no reliable medicinal drug to cure all cases of this disease. The results of the work were published in Proceedings of the National Academy of Sciences (PNAS) journal.

Each cell membrane has ion channels - protein pores that selectively conduct ions in and out of the cell. Due to their work membrane became electrically charged and has some transmembrane potential. At rest the potential kept on the same level. But under the influence of various signals certain ion channels may open or close, changing the flow of ions in and out of the cell and the charge of the membrane. As a result, certain cells (neurons, muscle cells, and gland cells) are activated and are able to respond to a signal.

However, sometimes channel-coding genes get damaged and cause inadequate response. For example, defects in certain domains of voltage-gated sodium channels Nav1.4 in muscle cells cause the membrane to "leak out" even when the channels are closed. Sodium ions penetrate the membrane and change the electric potential. In this case signals of the nervous system are not able to activate the muscle cells, and a patient develops paralysis. People with type 2 hypokalemic periodic paralysis suffer from muscle weakness up to total immobilization. Unfortunately, existing medicinal drugs against this condition are often inefficient.

"In our work we studied human voltage-gated ion channels, in particular the mutated forms of Nav1.4 channel from skeletal muscle. These mutations lead to a severe disease, type 2 hypokalemic periodic paralysis. We are the first to prove that there are natural chemical compounds able to block the leakage currents through mutated channels," explained Mikhail Petrovich Kirpichnikov, Doctor of Biological Sciences, member of the Russian Academy of Sciences, and dean of the Faculty of Biology, MSU.

Using a range of genetic methods, protein engineering, electrophysiology, NMR spectroscopy, and computer modeling, the scientists studied the reasons for abnormal activities in the channels damaged by mutation. For the first time they suggested a blocking agent for leakage currents - a toxin Hm-3 extracted from the venom of Heriaeus melloteei spider. According to the data obtained using site-directed mutagenesis, electrophysiology, NMR spectroscopy, and computer modeling, the toxin fixes the voltage-sensing domain of the channel in the position that prevents leakage of ions.

"The discovery of this toxin property gives us hope of developing efficient medicinal drugs for the treatment of patients with hypokalemic paralysis and other similar diseases. The model of interaction between the channel and the toxin gives us prospects for the development of new drugs," concludes Alexander Vasilevskiy, Candidate of Chemical Sciences, a lecturer at MSU, and the head of a laboratory at the Institute of Bioorganic Chemistry of the Russian Academy of Sciences.

The structural part of the work was commented on by Zakhar Shenkarev, Doctor of Physical and Mathematical Sciences, Professor of the Russian Academy of Sciences, a lecturer at Moscow Institute of Physics and Technology, and the group leader at the Institute of Bioorganic Chemistry of the Russian Academy of Sciences: "Studying the structure of ion channel complexes in the membrane is a difficult task. The main issue of our work was the instability of samples in the course of the NMR experiment. To solve it we had to come up with a range of new experimental methods that speeded up the process of structural data collection from several days to hours."

Männikkö R, Shenkarev ZO, Thor MG, Berkut AA, Myshkin MY, Paramonov AS, Kulbatskii DS, Kuzmin DA, Sampedro Castañeda M, King L, Wilson ER, Lyukmanova EN, Kirpichnikov MP, Schorge S, Bosmans F, Hanna MG, Kullmann DM, Vassilevski AA.
Spider toxin inhibits gating pore currents underlying periodic paralysis.
Proc Natl Acad Sci U S A. 2018 Apr 10. doi: 10.1073/pnas.1720185115.

Most Popular Now

Amgen and the Amgen Foundation commit up to $12.5 …

Amgen (NASDAQ:AMGN) and the Amgen Foundation announced an initial commitment of up to $12.5 million to support U.S. and global relief efforts to address critical needs in...

Novartis and life sciences companies commit expert…

Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics...

AstraZeneca to donate 9 million face masks to supp…

AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZ...

Roche response to COVID-19 pandemic

Roche Group (SIX: RO, ROG; OTCQX: RHHBY), provided an update on the various actions the company is taking to address the COVID-19 pandemic. On March 19, 2020, Roche co...

Singapore modelling study estimates impact of phys…

A new modelling study conducted in a simulated Singapore setting has estimated that a combined approach of physical distancing [2] interventions, comprising quarantine (f...

CAR macrophages go beyond T cells to fight solid t…

Chimeric antigen receptor (CAR) T cell therapy has been a game-changer for blood cancers but has faced challenges in targeting solid tumors. Now researchers from the Pere...

FDA approves first plasma therapy for Houston Meth…

Houston Methodist received FDA approval Saturday to become the first academic medical center in the nation to transfuse donated plasma from a recovered COVID-19 patient i...

Consignment of 30 million hydroxychloroquine table…

Novartis announced that Sandoz, its generics and biosimilars division, has started to ship a consignment of 30 million doses of hydroxychloroquine tablets to the US Depar...

Experimental AI tool predicts which COVID-19 patie…

An artificial intelligence tool accurately predicted which patients newly infected with the COVID-19 virus would go on to develop severe respiratory disease, a new study ...

Vivli to launch a portal for sharing data from COV…

In a visible sign of data sharing leadership, Vivli, the Center for Clinical Research Data has committed to serving the open science community through the launch of a COV...

Roche initiates Phase III clinical trial of Actemr…

Roche (SIX: RO, ROG; OTCQX: RHHBY) is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical tria...

Novartis commits to donate up to 130 million doses…

Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and...